Evaluating an Xcel Peptides Alternative: Catalog Breadth Is Not Verification

Published August 21, 2026 · Artemis Labs

Xcel Peptides alternative — when FDA reviewed xcelpeptides.com in October 2024, the resulting letter 694608-12102024 to Xcel Research LLC catalogued a long GLP-1-class product list: “RETA,” “CagriLean,” “SEMA,” and others. A wide catalog is quick to build; verification infrastructure — third-party HPLC and MS testing, a COA with every order — is not. Evaluate successors on the second, never the first.

Key findings

• The letter reads like an inventory. FDA’s October 2024 review of xcelpeptides.com, documented in warning letter 694608-12102024, lists product names as the site presented them: “RETA,” “CagriLean,” “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA,” “SURVODUTIDE,” “SERMORELIN.”
• Xcel was one of four that day. The letter belongs to FDA’s December 10, 2024 batch of four research-peptide vendors, all involving GLP-1-class compounds marketed under research-use-only labels that FDA found contradicted by website and social evidence.
• Breadth was the era’s signature. Peptide search demand rose roughly 398% year over year — on the order of 10.1 million monthly US searches by industry estimates — and product lists grew to meet it far faster than testing infrastructure did.

---

What did FDA’s October 2024 review of Xcel Peptides find?

FDA’s warning letter 694608-12102024 to Xcel Research LLC records a review of xcelpeptides.com conducted in October 2024. The letter’s most striking feature is its product list — the agency reproduced the names as the site listed them: “RETA,” “CagriLean,” “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA,” “SURVODUTIDE,” “SERMORELIN.” We report those names exactly as FDA’s letter lists them and attach nothing to them; the point is the list itself. FDA’s determination followed the pattern of the whole December 10, 2024 batch: GLP-1-class products marketed as “research use only” while, in the agency’s assessment, website evidence showed intended human use — with 15 working days to respond.

A list that runs seven product names deep is not incidental. It is a snapshot of a business model, and it is the reason this brief exists: the Xcel Research letter is the clearest document in the batch for thinking about what catalog size does and does not tell a researcher.

Why did peptide catalogs grow so fast?

Because demand arrived faster than infrastructure. Search interest in research peptides climbed roughly 398% year over year, reaching an estimated 10.1 million monthly US searches, and the GLP-1 class sat at the center of the wave. For a vendor, meeting that demand on paper is nearly free: a new catalog entry is a product photo, a description, and a price field. Xcel Research’s list — abbreviations, house blends, and full compound names side by side — is what that expansion looked like from the outside, as preserved in FDA’s own letter.

None of this is unique to one company, which is why no schadenfreude is warranted. The wave pulled in many vendors; the enforcement record that followed is broad. FDA has issued more than 100 warning letters to peptide and research-use-only sellers since September 2025 alone. The full chronology, vendor by vendor, is maintained on our peptide vendor closures 2025–2026 hub.

---

Verification scales slower than a product list

Here is the asymmetry that separates vendors. Adding a product to a catalog takes an afternoon. Verifying a product takes a supply chain: an independent laboratory relationship, HPLC purity analysis and mass-spectrometry identity confirmation for the material, a Certificate of Analysis generated and delivered with each order, and product documentation grounded in published literature, not in copy that writes itself. Each of those steps costs time and money per compound, per lot — which means verification capacity grows linearly and painfully while a product list can grow overnight.

So when a catalog doubles in a quarter, a researcher should ask the only question that matters: did the testing double with it? A long list is not evidence of anything except a CMS. The verification is the product.

Catalog-first versus verification-first vendors

The distinction is structural, and it is auditable from public pages. A catalog-first vendor expands the list to capture search demand and lets documentation lag: sparse or absent COAs, thin product pages, compound names styled for shoppers. A verification-first vendor lets the list grow only as fast as its testing does: every compound third-party verified for purity by HPLC and identity by MS, a COA in every order, references on every product page, and — just as telling — compounds it declines to carry because the analytical or literature basis is not there yet.

Artemis Labs operates on the second model, and we state it in checkable terms only: independent HPLC and MS verification, a COA with every order, roughly 500 PubMed and DOI citations across the catalog with a References section on every product page, honest counter-evidence where the literature contains it (the Sun 2025 Tβ4 finding appears on the relevant product page), no administration supplies sold, and no dosing or administration content anywhere. Every compound we supply is for laboratory research use only.

---

How should a researcher evaluate an Xcel Peptides alternative?

Invert the lesson of letter 694608-12102024: ignore the length of the list and audit the depth behind it.

• Pick one compound and pull its thread. Is there a lot-specific COA? Does it show third-party HPLC purity and MS identity data? Our walkthrough on reading a Certificate of Analysis shows what a complete one contains.
• Count citations, not products. A product page that cites the primary literature — and includes findings that complicate the compound’s reputation — signals a vendor doing the reading. Our research library shows the standard we hold ourselves to.
• Check conduct against labeling. No administration supplies in the cart, no outcome copy, research framing on every surface. The disclaimer question — why a research-use-only label cannot carry an operation that contradicts it — is the subject of our companion brief on choosing a Prime Peptides alternative.
• Run the vendor through the full checklist. Our peptide quality-assurance and supplier-evaluation guide assembles every criterion in one place.

---

Frequently asked questions

What products did FDA’s letter to Xcel Research LLC cite?

Warning letter 694608-12102024 lists the products as the site named them in October 2024: “RETA,” “CagriLean,” “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA,” “SURVODUTIDE,” and “SERMORELIN.” We reproduce the names solely as they appear in FDA’s letter, without attaching any characterization to the compounds.

Does a large catalog mean a vendor is untrustworthy?

No — breadth by itself is neutral; the question is whether verification kept pace with it. A wide catalog with per-compound third-party testing and per-order COAs is simply a mature vendor. A wide catalog without them is a list.

What counts as verification infrastructure?

Independent laboratory testing — HPLC for purity, mass spectrometry for identity — plus a Certificate of Analysis delivered with every order, and product documentation cited to published literature. It is the part of a peptide business that cannot be added with a website edit, which is exactly why it is the part worth auditing.

Where can I read letter 694608-12102024?

On FDA’s website, linked in the References below — the letter is public and short enough to read in ten minutes. Reading the original beats any summary of it, ours included.

References

1. FDA Warning Letter 694608-12102024, Xcel Research LLC — fda.gov
2. FDA Roundup, December 17, 2024 — fda.gov/news-events/press-announcements
3. FDA Warning Letters search index — fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters